Jeffrey J Landers
Overview
Explore the profile of Jeffrey J Landers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Croote D, Wong J, Creeks P, Aruva V, Landers J, Kwok M, et al.
J Allergy Clin Immunol
. 2024 Jul;
154(5):1241-1248.e7.
PMID: 39069172
Background: Existing therapeutic strategies are challenged by long times to achieve effect and often require frequent administration. Peanut-allergic individuals would benefit from a therapeutic that provides rapid protection against accidental...
2.
Saunders M, Rad L, Williams L, Landers J, Urie R, Hocevar S, et al.
Adv Healthc Mater
. 2024 May;
14(5):e2400237.
PMID: 38691819
Food allergy is a prevalent, potentially deadly disease caused by inadvertent sensitization to benign food antigens. Pathogenic Th2 cells are a major driver for disease, and allergen-specific immunotherapies (AIT) aim...
3.
Laghlali G, Wiest M, Karadag D, Warang P, OKonek J, Chang L, et al.
bioRxiv
. 2024 Apr;
PMID: 38586014
Current COVID-19 mRNA vaccines delivered intramuscularly (IM) induce effective systemic immunity, but with suboptimal immunity at mucosal sites, limiting their ability to impart sterilizing immunity. There is strong interest in...
4.
Jangra S, Landers J, Laghlali G, Rathnasinghe R, Warang P, Park S, et al.
NPJ Vaccines
. 2023 Jun;
8(1):96.
PMID: 37386041
Multiple FDA-approved SARS-CoV-2 vaccines currently provide excellent protection against severe disease. Despite this, immunity can wane relatively fast, particularly in the elderly and novel viral variants capable of evading infection-...
5.
Farazuddin M, Ludka N, Friesen L, Landers J, OKonek J, Kim C, et al.
Immunohorizons
. 2023 Jun;
7(6):480-492.
PMID: 37341756
Vitamin A and its biologically active metabolites, all-trans and 9-cis retinoic acid (RA), are thought to be important in generating and modulating immune function. However, RA modulates the function of...
6.
Jangra S, Landers J, Laghlali G, Rathnasinghe R, OKonek J, Janczak K, et al.
Res Sq
. 2023 Jan;
PMID: 36711479
Multiple FDA-approved SARS-CoV-2 vaccines provide excellent protection against severe disease. Despite this, immunity can wane relatively fast, particularly in the elderly and novel viral variants capable of evading infection- and...
7.
Hughes K, Saunders M, Landers J, Janczak K, Turkistani H, Rad L, et al.
Front Allergy
. 2022 Apr;
3:829605.
PMID: 35386645
Food allergy is a growing health concern worldwide. Current allergen-specific immunotherapy (AIT) approaches require frequent dosing over extended periods of time and may induce anaphylaxis due to allergen-effector cell interactions....
8.
Landers J, Janczak K, Shakya A, Zarnitsyn V, Patel S, Baker Jr J, et al.
Immunotherapy
. 2022 Feb;
14(7):539-552.
PMID: 35196877
Epicutaneous immunotherapy (EPIT) with peanut has been demonstrated to be safe but efficacy may be limited by allergen uptake through the skin barrier. To enhance allergen uptake into the skin,...
9.
Jangra S, Landers J, Rathnasinghe R, OKonek J, Janczak K, Cascalho M, et al.
Front Immunol
. 2021 Oct;
12:729189.
PMID: 34603303
Several SARS-CoV-2 vaccines have received EUAs, but many issues remain unresolved, including duration of conferred immunity and breadth of cross-protection. Adjuvants that enhance and shape adaptive immune responses that confer...
10.
Landers J, OKonek J
Adv Pharmacol
. 2021 Jun;
91:229-258.
PMID: 34099110
Food allergy is a growing public health epidemic with few available treatments beyond allergen avoidance and rescue medications for accidental exposures. A major focus of therapeutic development for food allergies...